White & Case advises Neopharmed Gentili on acquisition of exclusive rights to Navenibart in Europe from BioCryst Pharmaceuticals

Global law firm White & Case LLP has advised Neopharmed Gentili S.p.A. (Neopharmed), through its Irish affiliate, on a licensing agreement with BioCryst Pharmaceuticals, Inc. (BioCryst) for the commercialization in Europe of navenibart, an investigational treatment for hereditary angioedema (HAE).

Under the terms of the agreement, BioCryst will receive an upfront payment of US$70 million and may be eligible to receive up to an aggregate of US$275 million in regulatory and sales milestones, of which up to US$40 million is payable in up to three tranches upon the achievement of certain regulatory filings and approvals, as well as tiered royalties on net sales ranging from 18 percent to 30 percent.

This agreement represents a further strategic step in Neopharmed Gentili's evolution, building on the strong foundation established with the 2025 acquisition from BioCryst of the European commercial operations for ORLADEYO® (berotralstat). With the addition of navenibart, Neopharmed strengthens its rare disease platform, expanding its portfolio with an innovative therapy in late-stage development and is well positioned to become a leader in the HAE space in Europe.

The White & Case team that advised on the transaction was led by partner Michael Immordino (London & Milan) and included partner Leonardo Graffi (Milan & London), associates Elena Ruggiu and Valerio Bianchi (both Milan) and lawyer Chiara Pacini (Milan).

Press contact
For more information please speak to your local media contact.